DDInter898 DDInter1692
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Sodium dihydrogenphosphate is a sodium phosphate.
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Etodolac
Etodolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Linaclotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ketorolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Linaclotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linaclotide
Linaclotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Iloprost {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Iloprost {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may lead to a major life threatening interaction when taken with {v} Ephedrine
Ephedrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium phosphate, monobasic
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Etodolac and Etodolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sodium phosphate, monobasic
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sodium phosphate, monobasic